Truist Securities Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Asthika Goonewardene maintains a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and raises the price target from $17 to $26.

March 07, 2024 | 4:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities raises Iovance Biotherapeutics' price target from $17 to $26, maintaining a Buy rating.
The increase in price target by a reputable analyst firm like Truist Securities typically signals a strong bullish outlook on the stock, suggesting potential upside. This is based on the firm's analysis and confidence in the company's future performance. The maintenance of a Buy rating alongside a significant increase in the price target could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100